Could information improve patient access to new emerging drugs in rare cancer trials?

•Information is a very critical issue for patient access to new emerging drugs in rare cancer trials.•Information process must be accurately managed in all phases of the trials.•Information is crucial for patient awareness, empowerment, involvement and participation.